MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-02-2025
AngioDynamics EBITDA 2011-2026 | ANGO
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA AngioDynamics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -14.2 M | -165 M | -20.3 M | 878 K | -9.37 M | -143 M | 16 M | 42.9 M | 42.5 M | 32.5 M | 35.3 M | 39.3 M | 38.8 M | 22.6 M | 21.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 42.9 M | -165 M | -3.99 M |
Quarterly EBITDA AngioDynamics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.64 M | - | -7.38 M | -8.53 M | -6.31 M | - | -197 M | -9.56 M | 41.7 M | - | -4.19 M | -3.31 M | -5.64 M | -5.94 M | -400 K | -3.79 M | -1.1 M | -2.5 M | 554 K | -243 K | 1.46 M | 8.18 M | 1.46 M | 1.11 M | 4.38 M | 7.69 M | 4.38 M | 1.98 M | -530 K | 16.3 M | 5.92 M | 5.27 M | 5.93 M | 12.8 M | 5.93 M | 19.9 M | 9.72 M | 27.9 M | 9.72 M | 5.05 M | 7.32 M | 15.7 M | 8.29 M | 7.55 M | 9 M | 18.6 M | 9.94 M | 5.78 M | 7.31 M | 13.9 M | 7.38 M | 9.23 M | 7.27 M | 17.3 M | 3 M | 6.23 M | 5.85 M | 10.2 M | 5.85 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 41.7 M | -197 M | 2 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical instruments industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Luminex Corporation
LMNX
|
72.9 M | - | - | $ 1.75 B |  USA |
 |
Akers Biosciences, Inc.
AKER
|
-12.3 M | - | -9.52 % | $ 20.6 M | USA |
 |
AtriCure
ATRC
|
2.64 M | $ 31.07 | -1.26 % | $ 1.48 B | USA |
 |
Atrion Corporation
ATRI
|
37.7 K | - | - | $ 810 M | USA |
 |
The Cooper Companies
COO
|
1.06 B | $ 81.93 | -1.73 % | $ 16.3 B | USA |
 |
Alcon
ALC
|
580 M | $ 84.0 | 1.13 % | $ 40.4 B |  Schweiz |
 |
Antares Pharma, Inc.
ATRS
|
16.2 M | - | - | $ 955 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
-11.8 M | $ 10.9 | 9.0 % | $ 26.4 M | USA |
 |
Cantel Medical Corp.
CMD
|
123 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
33.9 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
518 M | - | -0.05 % | $ 10.3 B | USA |
 |
Baxter International
BAX
|
673 M | $ 19.1 | 0.45 % | $ 9.8 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
60 M | - | -0.02 % | $ 16.3 B | USA |
 |
Glaukos Corporation
GKOS
|
-95 M | $ 115.62 | -1.86 % | $ 5.6 B | USA |
 |
Haemonetics Corporation
HAE
|
337 M | $ 64.55 | -1.59 % | $ 3.25 B | USA |
 |
InfuSystem Holdings
INFU
|
15 M | $ 9.57 | 4.25 % | $ 198 M | USA |
 |
Isoray
ISR
|
-88.6 M | - | 0.03 % | $ 108 M | USA |
 |
iRhythm Technologies
IRTC
|
-36.7 M | $ 127.87 | 1.61 % | $ 4.09 B | USA |
 |
Repro Med Systems
KRMD
|
-9.4 M | $ 4.88 | 2.2 % | $ 223 M | USA |
 |
Harvard Bioscience
HBIO
|
3.37 M | $ 0.58 | 2.14 % | $ 24.6 M | USA |
 |
LeMaitre Vascular
LMAT
|
78.3 M | $ 106.91 | -0.87 % | $ 2.42 B | USA |
 |
Becton, Dickinson and Company
BDX
|
5.04 B | $ 171.22 | -1.8 % | $ 49.3 B | USA |
 |
Masimo Corporation
MASI
|
-164 M | $ 175.43 | 0.04 % | $ 9.35 B | USA |
 |
Microbot Medical
MBOT
|
-9.75 M | $ 2.47 | 3.28 % | $ 25.2 M |  Israel |
 |
BioLife Solutions
BLFS
|
-1.97 M | $ 20.59 | 2.06 % | $ 949 M | USA |
 |
Nephros
NEPH
|
-1.38 M | $ 3.92 | 1.29 % | $ 40.7 M | USA |
 |
electroCore
ECOR
|
-18.3 M | $ 7.9 | 3.81 % | $ 43.6 K | USA |
 |
Envista Holdings Corporation
NVST
|
332 M | $ 28.51 | -0.52 % | $ 4.79 B | USA |
 |
Retractable Technologies
RVP
|
-13.5 M | $ 0.68 | -3.05 % | $ 20.4 M | USA |
 |
ICU Medical
ICUI
|
244 M | $ 142.18 | -0.34 % | $ 3.5 B | USA |
 |
Intuitive Surgical
ISRG
|
3.55 B | $ 501.88 | 0.9 % | $ 179 B | USA |
 |
Pulse Biosciences
PLSE
|
-76.5 M | $ 18.29 | 1.89 % | $ 1.23 B | USA |
 |
Predictive Oncology
POAI
|
-10.8 M | - | - | $ 31.1 M | USA |
 |
Merit Medical Systems
MMSI
|
308 M | $ 74.53 | -0.43 % | $ 4.41 B | USA |
 |
NeuroMetrix
NURO
|
-8.69 M | - | 5.05 % | $ 9.02 M | USA |
 |
Repligen Corporation
RGEN
|
116 M | $ 126.05 | 2.43 % | $ 7.02 M | USA |
 |
OraSure Technologies
OSUR
|
-17.4 M | $ 3.0 | 0.67 % | $ 223 M | USA |
 |
ResMed
RMD
|
1.16 B | $ 258.94 | 0.22 % | $ 37.8 B | USA |
 |
Pro-Dex
PDEX
|
11.9 M | $ 48.51 | 2.1 % | $ 159 M | USA |
 |
STAAR Surgical Company
STAA
|
-83.4 M | $ 19.17 | 1.32 % | $ 950 M | USA |
 |
STERIS plc
STE
|
1.34 B | $ 244.67 | 0.62 % | $ 24.1 B | USA |
 |
Teleflex Incorporated
TFX
|
192 M | $ 119.41 | -2.24 % | $ 5.33 B | USA |
 |
Stereotaxis
STXS
|
-21.2 M | $ 2.22 | 3.74 % | $ 179 M | USA |
 |
Utah Medical Products
UTMD
|
17.4 M | $ 67.17 | 0.99 % | $ 244 M | USA |
 |
West Pharmaceutical Services
WST
|
756 M | $ 250.46 | -0.3 % | $ 18.1 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-70 M | $ 13.47 | 1.24 % | $ 2.69 B | USA |
 |
Milestone Scientific
MLSS
|
-6.72 M | $ 0.29 | 2.33 % | $ 23.1 M | USA |